Abstract Lapatinib is a new small molecule tyrosine kinase inhibitor. It targets both ErbB1 and ErbB2 (HER2) receptors and directly and reversibly acts on them to inhibit signaling. Since lapatinib has a low molecular weight, it can cross the blood-brain barrier. Thus, there is much interest in its potential effectiveness against brain metastases. Our patient was a 57-year-old postmenopausal woman with a non-contributory medical history.
Introduction
It is often difficult to cure metastatic breast cancer and recurrent breast cancer, except for some local recurrences. Approximately 10-16 % of the patients with metastatic breast cancer or recurrent breast cancer have brain metastases, and such patients have poor prognosis [1] . The effectiveness of pharmacotherapy is not high in the brain because of the blood-brain barrier. Therefore, the standard treatment of brain metastasis is radiation therapy. However, the molecularly targeted drug lapatinib has a low molecular weight and can cross the blood-brain barrier. Thus, there is much interest in its potential effectiveness against brain metastases [2] .
In this report, we present a case of HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura mater. The patient was effectively treated using lapatinib plus capecitabine before whole brain radiotherapy. We also include a brief literature review.
Case report
The patient was a 57-year-old postmenopausal woman with a non-contributory medical history. In September 2006, she underwent a partial mastectomy and axillary dissection for right breast cancer (T2N1M0, stage IIB). Pathological diagnosis was solid-tubular carcinoma, n? (6/23), nuclear grade 3, ly1, v0, estrogen receptor (ER) positive, progesterone receptor (PgR) negative, and HER2 3? [pT1cN2a M0-stageIIIA (UICC)]. Adjuvant chemotherapy consisted of 6 cycles of epirubicin and cyclophosphamide (EC 90 and 600 mg/m 2 , respectively, every 3 weeks) and subsequent oral anastrozole (1 mg/day). In May 2009, the patient developed reduced visual acuity and underwent examinations which revealed choroidal, lung, liver, bone, and lymph node metastases. She underwent radiation therapy (choroids 40 Gy and cervical vertebrae 40 Gy), and the oral drug was changed to high-dose toremifene (120 mg/day). In July 2009, the patient developed headache, vomiting, and seizures and was admitted to our hospital. MRI revealed multiple brain metastases and dura mater metastases, and CT revealed enlarged lung, liver, and bone metastases (tumor markers: CEA = 6.8 ng/ml and CA15-3 = 44.4 U/ml) ( Fig. 1a-d) . Since the metastases were life-threatening, we recommended trastuzumab plus weekly paclitaxel and whole brain radiotherapy. The patient did not consent to intravenous chemotherapy because she experienced severe nausea with EC administration. She also had strong concerns regarding whole brain radiotherapy and did not accept the aforementioned treatment. The patient underwent intravenous administration of glycerol and steroid for cerebral edema. She consented to oral chemotherapy consisting of lapatinib and capecitabine. In August 2009, administration of lapatinib (1,250 mg/ body, daily) plus capecitabine (2,000 mg/m 2 , day 1-14, every 3 weeks) was begun for treatment of brain and systemic metastatic lesions. Neurological symptoms improved on day 14. Administration of glycerol and steroid was discontinued, and the patient was discharged. In January 2010 (after completion of 7 cycles), examinations revealed that systemic, brain, and dura mater metastases had reduced in size, indicating a partial response (tumor markers: CEA = 3.5 ng/ml, CA15-3 = 24.9 U/ml) ( Fig. 2a-d ). There were no side effects. In March 2010 (after completion of 10 cycles), the patient exhibited progressive disease. Thus, the treatment was discontinued as per the patient's request (tumor markers: CEA = 5.6 ng/ ml, CA15-3 = 50.1 U/ml). In May 2010, the patient developed generalized seizures again and underwent whole brain radiotherapy (30 Gy). However, the patient did not improve and died in June 2010.
Discussion
Approximately 20-30 % of breast cancer cases show HER2 protein overexpression [3, 4] , and the prognosis of these patients has greatly improved owing to the development of trastuzumab [5, 6] . HER2-positive breast cancer is known to frequently metastasize to the brain [7, 8] . High effectiveness of trastuzumab cannot be expected for brain metastases because of its large molecular weight and inability to cross the blood-brain barrier [9, 10] . Thus, it is important to find an effective treatment to control brain metastatic lesions.
Lapatinib is a new small molecule tyrosine kinase inhibitor that targets both ErbB1 and ErbB2 (HER2) receptors. It directly and reversibly binds to the ATPbinding site of the kinase in the intracellular domain, resulting in the inhibition of ErbB1 and ErbB2 autophosphorylation and inhibition of signaling [11] .
Cameron et al. [12] conducted a randomized phase III trial involving patients with HER2-positive metastatic breast cancer or recurrent breast cancer that was resistant to trastuzumab. These patients were treated with capecitabine monotherapy or lapatinib plus capecitabine. Lapatinib plus capecitabine was shown to be more effective than capecitabine monotherapy (median progression-free survival 6.2 vs. 4.3 months, respectively; hazard ratio 0.57, 95 % CI 0.43-0.77, p \ 0.001) [12] . Lapatinib plus capecitabine is considered to be a promising treatment for HER2-positive metastatic breast cancer and recurrent breast cancer resistant to trastuzumab. Since lapatinib has a low molecular weight, it can pass through the blood-brain barrier. Thus, there is much interest in its potential effectiveness against brain metastases [2] . Several trials have shown that lapatinib was effective against HER2-positive breast cancer brain metastases.
Lin et al. [13] conducted a phase II trial involving subjects who had HER2-positive metastatic breast cancer to the brain that was resistant to trastuzumab and who had undergone whole brain radiotherapy. Lapatinib monotherapy was used in 236 patients, of whom 19 patients (8 %) had a tumor volume reduction of 50 % or more, and 50 patients (21 %) had a volume reduction of 20 % or more. A combination of lapatinib and capecitabine was used in 50 patients, of whom 11 patients (22 %) had a volume reduction of 50 % or more, and 20 patients (40 %) had a volume reduction of 20 % or more [13] .
Metro et al. [14] examined patients who had HER2-positive metastatic breast cancer to the brain after whole brain radiotherapy and who were treated with trastuzumab. The study compared patients who continued to use trastuzumab and those who switched to lapatinib plus capecitabine. Lapatinib plus capecitabine significantly prolonged the mean survival compared with trastuzumab (16.7 vs. 27.9 months, p = 0.01) [14] .
Radiation therapy is the standard treatment of breast cancer brain metastasis. There has also been a trial regarding lapatinib plus capecitabine used up front. Bachelot et al. [15] conducted a phase II trial involving patients with HER2-positive metastatic breast cancer to the brain. These patients received lapatinib plus capecitabine before whole brain radiotherapy. The results showed that, of 43 patients, 29 (67.4 %, 95 % CI 51-81) achieved an objective central nervous system response (CNS-OR), which was defined as a 50 % or more volume reduction of CNS lesions. Time to progression was 5.5 months (95 % CI 3.9-5.9). There were 32 patients (74.4 %) who had undergone whole brain radiotherapy owing to progression of CNS lesions. The median time until whole brain radiotherapy was 8.3 months (95 % CI 5.1-11.7), and the 6-month survival rate was 90.9 % (95 % CI 77.4-96.5). The above results suggest that lapatinib plus capecitabine can achieve high response rates in patients with HER2-positive breast cancer who were newly diagnosed with brain metastases, and that lapatinib plus capecitabine is a promising new treatment option for such patients [15] .
In our case, the patient had severe side effects of intravenous adjuvant chemotherapy. Thus, the patient did not consent to the use of trastuzumab. Since lapatinib plus capecitabine is administered orally, patient acceptance is high. Our patient also accepted oral lapatinib plus capecitabine. Radiation therapy was not performed as per the patient's request, and lapatinib plus capecitabine was used for brain metastases and systemic metastases. The results indicated that the treatment was effective for these metastases. (In January 2010, MRI revealed a tumor volume reduction rate of 31 % for brain metastases and 65 % for dura mater metastases.) Neurological symptoms such as seizures, vomiting, and headache were controlled, and metastases were well controlled. Time to progression was 7.5 months, and good results were obtained for breast cancer brain metastases without radiation therapy. In addition, there were no side effects such as diarrhea or hand-foot syndrome.
It is often difficult to cure metastatic breast cancer and recurrent breast cancer. The prognosis of brain metastasis is particularly poor, and improvement of quality of life and extension of survival are the objectives of treatment for brain metastasis. Since lapatinib plus capecitabine is orally administered, patient acceptance is high and these drugs can become a treatment option for breast cancer brain metastasis.
Conclusion
In this report, we presented a case of HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura mater. The patient was effectively treated using lapatinib plus capecitabine before whole brain radiotherapy. The result of our case showed that lapatinib plus capecitabine can be an effective treatment option for breast cancer brain metastases.
